New growth model
Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Kripa Mahalingam - July 26, 2019
Tricky Transition
Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs
N Mahalakshmi - July 16, 2019
Inflection point
Laurus Labs is crucially poised, as investors look forward to its R&D efforts finally paying off
Khushboo Balani - April 04, 2018
Indian Ingenuity
Outstanding companies that exemplify the power of Indian enterprise
N Mahalakshmi - June 07, 2017
Master Innovator
Vishnukant Bhutada’s big bet on oncology has catapulted Shilpa Medicare into the global generics space
Shilpa Elizabeth Abraham - June 09, 2017
Daljeet Singh Kohli
The time has come for Shilpa Medicare to reap the benefits of the hard work done by its management over the past few years
January 13, 2017
Inching towards the exit?
Tano Capital is cashing in some of its chips at Shilpa Medicare
Jash Kriplani - July 07, 2016
Manish Bhandari
Vallum Capital Advisors' Manish Bhandari foresees a bright future for oncology specialist Shilpa Medicare
May 11, 2015